Rite Aid — Q2 FY2019 Earnings Presentation
34 slides from Rite Aid's earnings presentation, Sep 27, 2018
Slide 1: Cautionary Statement Regarding Forward Looking Statements
Cautionary Statement Regarding Forward Looking Statements Statements in this presentation that are not historical, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, stat
Slide 2: Cautionary Note Regarding Pro Forma Information
Cautionary Note Regarding Pro Forma Information The following presentation provides certain pro forma information regarding the impact of Rite Aid’s pending sale of distribution centers and assets to WBA on Rite Aid’s results of operations and capital structure. The pro forma information is for illu
Slide 3: Non-GAAP Financial Measures
NON-GAAP FINANCIAL MEASURES The following presentation includes the non-GAAP financial measures, Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share, Pro Forma Adjusted EBITDA, Adjusted EBITDA Gross Profit and Adjusted EBITDA SG&A. Rite Aid defines Adjusted EBIT
Slide 4: Strategy Update
Quarter Ended September 1, 2018 STRATEGY UPDATE
Slide 5: Building a Leader in Health and Wellness
BUILDING A LEADER IN HEALTH AND WELLNESS 6 EXPANDING OUR OMNICHANNEL CAPABILITIES Grow Front End through convenient shopping & tailored offering Leverage our valuable wellness brand Refine merchandising across Own Brand, assortment and layout while tailoring to key markets Relaunch wellness+ to driv
Slide 6: Network Access
Medicare Part D In all OPEN networks In two national and two regional preferred Medicare Part D plans Continued discussions with payors for 2020 preferred access Commercial Networks Multi-year agreements in place with top payors Continued dialogue with payors to identify performance-based network op
Slide 7: Clinical Initiatives to Drive Script Growth
CLINICAL INITIATIVES TO DRIVE SCRIPT GROWTH Drive Adherence Capitalize on launch of Shingrix and ancillary immunizations Centralize MTM activities to improve output Improve Rite Care through development Improve customer experience through technology Enhance Delivery Model A I M ADHERENCE IMMUNIZATIO
Slide 8: Immunizations by fiscal year
Immunizations by fiscal year (in thousands) 9
Slide 9: Wellness Store Renovations
Comp results for Wellness stores continue to exceed the chain average(1) Front-end sales growth outperformance of 93 bps in Q2 Fiscal 2019 Script count growth outperformance of 113 bps in Q2 of Fiscal 2019 Remodeled Stores Since 2012 WELLNESS STORE RENOVATIONS Calculation compares the comp results o
Slide 10: Wellness+ Rewards Program
Wellness+ rewards program Program changes in January 2018 have been successful Customer/member engagement has grown significantly with introduction of Bonus Cash Integration of industry leading loyalty management platforms (Symphony Retail, Amplify and Redpoint) is currently being integrated to driv
Slide 11: Bonus Cash Has Significantly Increased Customer Engagement
1 in 5 transactions today includes Bonus Cash Nearly double the impact of Plenti last year BONUS CASH HAS SIGNIFICANTLY INCREASED CUSTOMER ENGAGEMENT 12
Slide 12: Localized Product Assortment
Being relevant and local will be a key differentiator for the new Rite Aid Appropriate ethnic assortment to match core demographic Consumables, beauty, and seasonal Product assortment that resonates with local community Consumables and apparel Expanded DME in select communities Localized Instore Mar
Slide 13: Rite Aid Own Brands
Six key brands with over 4,200 items throughout the store and sales over $800mm A strategic point of difference for Rite Aid, offering many exclusive items and great value for our customers Commitment to quality with all products to meet or exceed National Brand standards RITE AID OWN BRANDS 14
Slide 14: Building Strong Relationships Through Omnichannel Offerings
BUILDING STRONG RELATIONSHIPS WITH OUR CUSTOMERS THROUGH OMNICHANNEL OFFERINGS Pharmacy Drive-Through Pharmacy Delivery Pharmacy B-to-B Flu Clinics EnvisionRx Retail Stores RediClinic Mobile App RiteAid.com E-Commerce 15
Slide 15: Rapidly Growing Medicare Part D Business
RAPIDLY GROWING MEDICARE PART D BUSINESS (in thousands) Lives covered by EnvisionRx (1) Represents estimated enrollment at the end of calendar 2018. (1) 16
Slide 16: Pharmacy Business Stabilization
Rate stabilization expected to continue in Fiscal 2020 Reimbursement rate trends have improved over the last year Generic Effective Rate contracts for 80% of our business provide increased predictability on reimbursements and access for the coming year PHARMACY BUSINESS STABILIZATION 17
Slide 17: Optimize Pharmacy Purchasing
WBAD generic purchasing option Option expires May 2019 Requires brands to be sourced through ABC Benefit being verified in clean room process RFP process to achieve lowest possible drug cost prior to exercising option WBAD option, possible bids from McKesson and Cardinal Timing Evaluation process to
Slide 18: Financial Update
Quarter Ended September 1, 2018 FINANCIAL UPDATE
Slide 19: Q2 - Fiscal 2019 Summary
Q2 - FISCAL 2019 SUMMARY 21 ($ in millions, except per share amounts) Note: Data on this slide and throughout the presentation is on a continuing operations basis. 13 Weeks Ended Sept. 1, 2018 13 Weeks Ended Sept 2, 2017 Revenue $ 5,421.4 $ 5,345.0 Net (Loss) $ (352.3) $ 188.4 Net (Loss) Income per
Slide 20: Reconciliation of Net (Loss) Income to Adjusted EBITDA
Q2 - FISCAL 2019 RECONCILIATION OF NET (LOSS) INCOME TO ADJUSTED EBITDA 22 ($ in thousands) ($ in thousands) 13 Weeks Ended Sept. 1, 2018 13 Weeks Ended Sept. 2, 2017 Net (Loss) Income - Continuing Operations $ (352,348) $ 188,360 Adjustments: Interest expense 56,233 50,857 Income tax (benefit) expe
Slide 21: Reconciliation of Net (Loss) Income to Adjusted Net Loss
Q2 - FISCAL 2019 RECONCILIATION OF NET (LOSS) INCOME TO ADJUSTED NET LOSS 23 ($ in thousands, except per share amounts) ($ in thousands) 13 Weeks Ended Sept. 1, 2018 13 Weeks Ended Sept. 2, 2017 Net (Loss) Income $ (352,348) $ 188,360 Add back - Income tax (benefit) expense (106,559) 117,450 (Loss)
Slide 22: Q2 - Fiscal 2019 Summary - Retail Pharmacy Segment
Q2 - FISCAL 2019 SUMMARY - RETAIL PHARMACY SEGMENT 24 ($ in millions) (1) Refer to slides 27 and 28 for the reconciliations of these non-GAAP measures to their applicable GAAP measures. 13 Weeks Ended Sept. 1, 2018 13 Weeks Ended Sept. 2, 2017 Revenue $ 3,911.5 $ 3,901.8 Adjusted EBITDA Gross Profit
Slide 23: Q2 - Fiscal 2019 Summary - Retail Pharmacy Segment
Retail Pharmacy Segment revenue increased $9.7 million. Same store sales increased 1.0%, driven primarily by a 1.1% increase in same store script growth. Adjusted EBITDA Gross Profit decreased $7.6 million and Adjusted EBITDA Gross Margin decreased by 26 bps. The Gross Margin decrease was driven by
Slide 24: Reconciliation of Adjusted EBITDA Gross Profit - Retail Pharmacy Segment
RECONCILIATION OF ADJUSTED EBITDA GROSS PROFIT - RETAIL PHARMACY SEGMENT 26 ($ in thousands) Reconciliation of Adjusted EBITDA Gross Profit Retail Pharmacy Segment ($ in thousands) 13 Weeks Ended Sept. 1, 2018 13 Weeks Ended Sept. 2, 2017 Revenues $ 3,911,512 $ 3,901,842 Gross Profit 1,051,637 1,058
Slide 25: Reconciliation of Adjusted EBITDA SG&A - Retail Pharmacy Segment
RECONCILIATION OF ADJUSTED EBITDA SG&A - RETAIL PHARMACY SEGMENT 27 ($ in thousands) Reconciliation of Adjusted EBITDA SG&A Retail Pharmacy Segment ($ in thousands) 13 Weeks Ended Sept. 1, 2018 13 Weeks Ended Sept. 2, 2017 Total Revenues $ 3,911,512 $ 3,901,842 Selling, general and administrative ex
Slide 26: Pharmacy Services Segment Results
PHARMACY SERVICES SEGMENT RESULTS 28 ($ in millions) 13 Weeks Ended Sept. 1, 2018 13 Weeks Ended Sept. 2, 2017 Revenues $ 1,561.8 $ 1,492.8 Cost of Revenues 1,452.3 1,389.6 Gross Profit 109.5 103.2 Selling, General and Administrative Expense (85.0) (75.4) Addback: Depreciation and Amortization 20.5
Slide 27: Q2 - FY 2019 Summary - Pharmacy Services Segment
Revenues increased $69.0 million, primarily due to an increase in our Medicare Part D membership Adjusted EBITDA decreased $4.3 million, primarily due to margin compression in our commercial business and SG&A investments we have made to support our current year and future growth Q2 - FY 2019 SUMMARY
Slide 28: Comparable Store Sales Growth
FY 2018 FY 2016 FY 2017 Front End Sales Rx Sales COMPARABLE STORE SALES GROWTH 30 Script Count (1) (1) Script count growth shown on a 30-day equivalent basis. FY 2019 5.0% 3.3% 1.8% 0.5% 0.4% - 3.4% - 4.0% - 4.7% - 5.5% - 4.9% - 3.5% - 2.3% - 0.1% 1.6% 0.9% 0.8% 0.7% 0.1% 1.5% 0.5% 0.1% 0.1% - 1.1%
Slide 29: Capitalization Table
CAPITALIZATION TABLE 31 ($ in thousands) Note: Debt in the capitalization table is shown net of unamortized debt issuance costs. Capitalization Table & Leverage ($ in thousands) ############### March 3, 2018 Secured Debt: Senior secured revolving credit facility due January 2020 $ 1,326,367 $ (13,07
Slide 30: Pro Forma Leverage Ratio
PRO FORMA LEVERAGE RATIO 32 ($ in thousands) Sept. 1, 2018 Total Debt: $ 3,526,946 Less: cash and cash equivalents 132,468 Less: distribution center sale proceeds 218,314 Pro Forma Net Debt $ 3,176,164 Pro Forma Adjusted EBITDA: Retail Pharmacy Segment 430,989 Pro Forma adjustment for TSA Fees 39,60
Slide 31: FY 2019 Guidance
FY 2019 GUIDANCE 33 ($ in thousands) RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED EBITDA GUIDANCE YEAR ENDING MARCH 2, 2019 (In thousands, except per share amounts) (unaudited) Guidance Range Low High Total Revenues $ 21,700,000 $ 22,
Slide 32: FY 2019 Guidance (cont.)
FY 2019 GUIDANCE (cont.) 34 ($ in thousands, except per share amounts) RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED NET INCOME GUIDANCE YEAR ENDING MARCH 2, 2019 (In thousands, except per share amounts) (unaudited) Guidance Range Low
Slide 33: FY 2019 Guidance (cont.)
FY GUIDANCE (cont.) (Sin thousands, except per share amounts) Guidance Range Low Hi Net loss $ (485,000) $ ‘Add back Income tax benefit 130,000) (125,000) Loss before income taxes (615,000) Adjustments: ‘Amortization expense 120,000 120,000 UFO charge 35,000 35,000 Goodwill and intangible asset impa
Slide 34: Slide 34